[SCHEDULE 13G/A] Immix Biopharma, Inc. Amended Passive Investment Disclosure
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Immix Biopharma, Inc. Schedule 13G/A amendment shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared beneficial ownership of 1,750,200 shares of Common Stock (CUSIP 45258H106), representing 3.3% of the class as disclosed on the cover pages. The filing states the shares are held by entities subject to voting and investment discretion of Millennium Management LLC and/or other managers affiliated with Millennium Group Management LLC and Mr. Englander and includes a Joint Filing Agreement dated May 1, 2026.
Insights
Large manager reports a passive, shared 3.3% position via managed entities.
The filing lists 1,750,200 shares held through entities subject to Millennium’s voting and investment discretion, indicating aggregated reporting by manager-affiliated vehicles rather than direct individual ownership.
Disclosure includes a Joint Filing Agreement dated May 1, 2026; timing and exact holder entities are in exhibit references. Subsequent filings would show if this position changes.
Schedule 13G/A amendment aligns with passive/beneficial-owner reporting conventions.
The amendment attributes shared voting and dispositive power of 1,750,200 shares (3.3%) across Millennium entities and Mr. Englander, with customary boilerplate that the disclosure is not itself an admission of beneficial ownership.
Includes signatures and an executed Joint Filing Agreement; filings appear procedurally complete for aggregated reporting.
Key Figures
Key Terms
Joint Filing Agreement regulatory
beneficially owned regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.